- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Millennium Pharmaceuticals Inc. (MLNM)
by latest | most commented
-
Will M&A Activity Boost PowerShares Dynamic Biotech & Genome ETF?
-
Russell 1,000 Stocks Up and Down the Most Since the 3/10 Bottom
-
Today's 52-Week High List: Energy Dominates
-
General Electric's Healthcare Disappointment
-
Last Week's Winners and Losers
-
Millennium Has Nothing to Fear from a Takeda Takeover
-
Wall Street Breakfast: Must-Know News
-
Earnings Preview: Millennium Pharmaceuticals
-
Strongest Upward Revisions Heading Into Earnings
-
Russell 1,000's Best, Worst Performers Since the 10/9 Top
-
Who are the Russell 1,000's Most Overbought and Oversold Stocks?
-
PBE: Large Biotech Meets Small Biotech
-
Millennium’s Velcade a Phase III Trial Success
-
Thursday's Options Report: Apple, Ford, Kraft, Baidu, Emulex, Millennium
-
Cancer Stocks: The Bleeding Slows
-
Millenium Pharmaceuticals A Sell On Strong Competition, Slowed Growth
-
Cancer Stocks Hammered Once Again
-
Cancer Stocks Slide Again
-
Cancer Stocks Plunge Following ASCO Meeting
-
Cancer Stocks Soar With Annual ASCO Meeting
-
Cancer Stocks on the Go: Winners and Losers
-
Biotechs Make Appearances in Best and Worst Lists of WSJ Review
-
Report From JPMorgan's HealthCare Conference: The Spinal Business Is Hot
-
Millenium Ends Its Bid For AnorMED, Leaving Genzyme On Top
-
Bidding War Continues for AnorMED's Stem Cell Drug
-
Millenium Beats Genzyme, Gets AnorMED's Stem Cell Drug
-
Stocks Covered by The Biotech Stock Blog